OR WAIT null SECS
© 2023 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 23, 2021.
An analysis of medical data from a major database in Taiwan suggests an inadequate response to DMARD therapy among patients with rheumatoid arthritis was associated with increased risk of acute coronary syndrome.
Click the image to view the story.
Rheumatology Network sat down with Rebecca Manno, MD, MHS, to discuss the American College of Rheumatology State of the Art (ACR SOTA) Clinical Symposium, which ran from April 9-11.
Click the image to view the story.
A treat-to-target strategy is recommended by the American College of Rheumatology for managing rheumatoid arthritis patients over a non-targeted approach. Test your knowledge of the rationale for treat-to target and how it should be implemented in our quiz.
Click the image to view the story.
Long-term administration of rituximab may be associated with more severe COVID-19 outcomes, including intensive care unit (ICU) admission or death, especially for those with other comorbidities.
Click the image to view the story.
While further studies are needed, the results indicate that resolving the SDoH issues, via programs like the iCMP, may decrease healthcare costs while equalizing care and outcomes for both patients with SLE and those with complex chronic conditions in general.
Click the image to view the story.